Trial results

A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

NCT06131372 on ClinicalTrials.gov · last registry update 2026-04-01

An unusually large phase 2: 626 participants, more than double the 114 typical for the stage. The sponsor logged completion for 24 September 2025. Primary outcome, as filed: Change in urinary albumin-to-creatinine ratio (UACR). semaglutide is already approved in the US for chronic kidney disease and obesity, so this is asking a further question rather than establishing the drug works at all.

Status

COMPLETED

Phase

P2

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

Novo Nordisk A/S

Sponsor type

Industry

Enrollment

626

Started

2024-04-01

Primary completion

2025-09-24 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in urinary albumin-to-creatinine ratio (UACR)

Conditions studied

Chronic Kidney Disease · Type 2 Diabetes · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.